






















Reference Data

Business segments and major products

Segment	Description	Major products					
Imaging Products Business	Digital camera-interchangeable lens type Interchangeable lens Cinema camera	 Mirrorless Camera [Z5II]	 Mirrorless Camera [Z50II]	 [NIKKOR Z 28-135mm f/4 PZ]	 [V-RAPTOR [X] Z Mount]		
Precision Equipment Business	FPD lithography system Semiconductor lithography system Alignment station Measuring & inspection system	 FPD Lithography System [FX-88S]	 ArF Immersion Scanner [NSR-S636E]	 Alignment Station [Litho Booster]	 Automatic Macro Inspection System [AMI-5700]		
Healthcare Business	Biological microscope (Life Science Solutions) Retinal diagnostic imaging system (Eye Care Solutions) Contract Cell Development and Manufacturing	 Confocal Microscope System [AX/AX R]	 Ultra-Widefield Retinal Diagnostic Imaging System with Integrated UWF-Guided Swept Source OCT [Silverstone]	 Contract Cell Development and Manufacturing			
Components Business	EUV related components Optical parts, Optical components Encoders, Measuring and inspection systems Photomask substrates for FPD	 Optical Components	 Multi-turn External Battery-Free Absolute Encoder [MAR-M700MFA]	 Video Measuring System [NEXIV VMF-K Series]	 Industrial Microscope [ECLIPSE LV100ND LED]	 Versatile Large-Envelope X-ray and CT System [VOXLS 40 C 450]	 Photomask Substrates for FPD
Digital Manufacturing Business	Metal 3D printer Optical processing machine 3D scanner Contract material processing	 Metal 3D Printer [NXG XII 600E]	 Material Processing Machine [Lasermeister LM300A]	 3D Scanner [Lasermeister SB100]	 Contract Material Processing		

Forecast for the Year Ending March 31, 2026:

Forecast by Segment (Details of Tariff Impacts)

Billions of Yen		Forecast without Tariff Impacts (Aug. 7)			Tariff Impacts (Aug. 7)			New Forecast (Aug. 7) (B)		
		1H	2H	Full Year	1H*	2H	Full Year	1H	2H	Full Year
Imaging Products Business	Revenue	142.0	150.0	292.0	-2.0	-3.0	-5.0	140.0	147.0	287.0
	Operating profit	16.0	21.0	37.0	-2.0	-3.0	-5.0	14.0	18.0	32.0
Precision Equipment Business	Revenue	72.0	113.0	185.0				72.0	113.0	185.0
	Operating profit	0.5	11.5	12.0				0.5	11.5	12.0
Healthcare Business	Revenue	50.0	62.0	112.0				50.0	62.0	112.0
	Operating profit	0.0	6.0	6.0	-1.0	-1.0	-2.0	-1.0	5.0	4.0
Components Business	Revenue	35.0	44.0	79.0				35.0	44.0	79.0
	Operating profit	3.5	6.5	10.0				3.5	6.5	10.0
Digital Manufacturing Business	Revenue	14.0	19.0	33.0				14.0	19.0	33.0
	Operating profit	-5.5	-3.0	-8.5		-0.5	-0.5	-5.5	-3.5	-9.0
Others	Revenue	2.0	2.0	4.0				2.0	2.0	4.0
	Operating profit	0.5	2.0	2.5				0.5	2.0	2.5
Corporate expenses, etc.	Operating profit	-20.0	-10.5	-30.5				-20.0	-10.5	-30.5
	Broken out: Expense related to investment in growth	-9.0	-9.0	-18.0				-9.0	-9.0	-18.0
	Broken out: Expense for administration department	-9.0	-2.0	-11.0				-9.0	-2.0	-11.0
	Broken out: Elimination of intersegment transactions	-2.0	0.5	-1.5				-2.0	0.5	-1.5
Consolidated	Revenue	315.0	390.0	705.0	-2.0	-3.0	-5.0	313.0	387.0	700.0
	Operating profit	-5.0	33.5	28.5	-3.0	-4.5	-7.5	-8.0	29.0	21.0

Assumptions for US tariff impacts: Tax rates from Aug. onwards: Japan/EU 15%, Thailand 19%, China 55%, UK 10%

The Year Ended March 31, 2025: One-Time Costs by Segment

Billions of Yen	FY2025/3					
	Q1	Q2	Q3	Q4	Full Year	Details
Imaging Products Business	-0.5	-	-	-1.4	-1.9	Q1: RED acquisition related expenses -0.5 Q4: MRMC* fixed asset impairment losses -0.8, intellectual property related expenses -0.6
Precision Equipment Business	-	-	-	-14.1	-14.1	Impairment of fixed assets -7.8, inventory write-downs -5.0, restructuring costs (optimization of service bases) -1.2
Healthcare Business	-0.5	-0.4	-0.4	-0.7	-2.0	Eye Care Solutions investigation costs, etc.
Components Business	-	-	-0.8	-1.0	-1.8	Restructuring costs (optimization of organization of the formerly Industrial Metrology Business) -1.8
Digital Manufacturing Business	-	-	-	-	-	
Others (incl. Corporate expenses, etc.)	-	-5.1	-1.3	-0.7	-7.1	Q2: HQ relocation costs Q3/Q4: restructuring costs (footprint reorganization) -1.8 etc.
Consolidated	-1.0	-5.5	-2.6	-18.1	-27.2	

Out of One-Time Costs, total of ¥4.9B for restructuring costs

The Year Ending March 31, 2026: One-Time Costs by Segment

Billions of Yen	FY2026/3	
	Q1	Details
Imaging Products Business	-	
Precision Equipment Business	-	
Healthcare Business	-0.5	Eye Care Solutions investigation costs, etc.
Components Business	-	
Digital Manufacturing Business	-	
Others (incl. Corporate expenses, etc.)	-0.6	Expenses related to footprint reorganization
Consolidated	-1.1	

Forecast for the Year Ending March 31, 2026: Financial Highlights

Billions of Yen	FY2023/3	FY2024/3	FY2025/3			FY2026/3 Forecast		
	Full Year	Full Year	1H	2H	Full Year	1H	2H	Full Year
Revenue	628.1	717.2	332.7	382.5	715.2	313.0	387.0	700.0
Operating profit	54.9	39.7	5.8	-3.4	2.4	-8.0	29.0	21.0
% vs Revenue	8.7%	5.5%	1.7%	-0.9%	0.3%	-2.6%	7.5%	3.0%
Profit before tax	57.0	42.6	4.4	0.1	4.5	-6.0	31.0	25.0
% vs Revenue	9.1%	5.9%	1.3%	0.0%	0.6%	-1.9%	8.0%	3.6%
Profit attributable to owners of parent	44.9	32.5	2.9	3.2	6.1	5.0	22.0	27.0
% vs Revenue	7.2%	4.5%	0.9%	0.8%	0.9%	1.6%	5.7%	3.9%
FCF	-112.1	-10.6	-21.7			-		
ROE	7.4%	5.0%	0.9%			4.2%		
EPS	¥125.46	¥94.03	¥17.86			¥82.08		
Annual Dividends	¥45	¥50	¥50			¥50		
Exchange Rate: US\$	¥135	¥145	¥153	¥152	¥153	¥145	¥145	¥145
EURO	¥141	¥157	¥166	¥162	¥164	¥159	¥155	¥157

Note: The numbers of issued shares assumed for EPS forecast calculation: approx. 328.9M shares

Forecast for the Year Ending March 31, 2026: Financial Highlights

Billions of Yen	FY2025/3 Actual (A)			FY2026/3 Forecast (B)			Change (B)-(A)		
	1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
Revenue	332.7	382.5	715.2	313.0	387.0	700.0	-19.7	+4.5	-15.2
Operating profit	5.8	-3.4	2.4	-8.0	29.0	21.0	-13.8	+32.4	+18.6
% vs Revenue	1.7%	-0.9%	0.3%	-2.6%	7.5%	3.0%	-4.3P	+8.4P	+2.7P
Profit before tax	4.4	0.1	4.5	-6.0	31.0	25.0	-10.4	+30.9	+20.5
% vs Revenue	1.3%	0.0%	0.6%	-1.9%	8.0%	3.6%	-3.2P	+8.0P	+3.0P
Profit attributable to owners of parent	2.9	3.2	6.1	5.0	22.0	27.0	+2.1	+18.8	+20.9
% vs Revenue	0.9%	0.8%	0.9%	1.6%	5.7%	3.9%	+0.7P	+4.9P	+3.0P
ROE	0.9%			4.2%			+3.3P		
EPS	¥17.86			¥82.08			+¥64.22		
Annual Dividends	¥50			¥50			-		
Exchange Rate: US\$	¥153	¥152	¥153	¥145	¥145	¥145	-¥8	-¥7	-¥8
EURO	¥166	¥162	¥164	¥159	¥155	¥157	-¥7	-¥7	-¥7

Note: The numbers of issued shares assumed for EPS forecast calculation: approx. 328.9M shares


Forecast for the Year Ending March 31, 2026: Performance by Segment

Billions of Yen		FY2025/3 Actual (A)			FY2026/3 Forecast (B)			Change (B)-(A)		
		1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
Imaging Products Business	Revenue	151.7	143.6	295.3	140.0	147.0	287.0	-11.7	+3.4	-8.3
	Operating profit	28.8	12.5	41.3	14.0	18.0	32.0	-14.8	+5.5	-9.3
Precision Equipment Business	Revenue	81.5	120.4	201.9	72.0	113.0	185.0	-9.5	-7.4	-16.9
	Operating profit	0.9	0.6	1.5	0.5	11.5	12.0	-0.4	+10.9	+10.5
Healthcare Business	Revenue	55.1	61.3	116.4	50.0	62.0	112.0	-5.1	+0.7	-4.4
	Operating profit	1.3	5.4	6.7	-1.0	5.0	4.0	-2.3	-0.4	-2.7
Components Business	Revenue	30.4	43.7	74.1	35.0	44.0	79.0	+4.6	+0.3	+4.9
	Operating profit	1.4	5.7	7.1	3.5	6.5	10.0	+2.1	+0.8	+2.9
Digital Manufacturing Business	Revenue	11.7	11.6	23.3	14.0	19.0	33.0	+2.3	+7.4	+9.7
	Operating profit	-6.4	-8.8	-15.2	-5.5	-3.5	-9.0	+0.9	+5.3	+6.2
Others	Revenue	2.0	2.0	4.0	2.0	2.0	4.0	±0.0	±0.0	±0.0
	Operating profit	0.6	2.3	2.9	0.5	2.0	2.5	-0.1	-0.3	-0.4
Corporate expenses, etc.	Operating profit	-20.9	-21.1	-42.0	-20.0	-10.5	-30.5	+0.9	+10.6	+11.5
	Broken out: Expense related to investment in growth	-9.9	-10.5	-20.4	-9.0	-9.0	-18.0	+0.9	+1.5	+2.4
	Broken out: Expense for administration department	-12.0	-11.5	-23.5	-9.0	-2.0	-11.0	+3.0	+9.5	+12.5
	Broken out: Elimination of intersegment transactions	1.0	0.9	1.9	-2.0	0.5	-1.5	-3.0	-0.4	-3.4
Consolidated	Revenue	332.7	382.5	715.2	313.0	387.0	700.0	-19.7	+4.5	-15.2
	Operating profit	5.8	-3.4	2.4	-8.0	29.0	21.0	-13.8	+32.4	+18.6

1st Quarter of the Year Ending March 31, 2026 : Quarterly Performance by Segment

Billions of Yen		FY2025/3				FY2026/3
		Q1	Q2	Q3	Q4	Q1
Imaging Products Business	Revenue	83.7	68.0	83.9	59.7	80.0
	Operating profit	17.8	11.0	15.0	-2.5	11.0
Precision Equipment Business	Revenue	33.1	48.4	43.4	77.0	33.8
	Operating profit	-2.1	3.0	-1.5	2.1	1.8
Healthcare Business	Revenue	26.2	28.9	26.4	34.9	23.1
	Operating profit	-0.6	1.9	0.8	4.6	-1.8
Components Business	Revenue	13.8	16.6	18.6	25.1	15.1
	Operating profit	-0.1	1.5	2.2	3.5	1.8
Digital Manufacturing Business	Revenue	5.9	5.8	6.5	5.1	5.0
	Operating profit	-3.5	-2.9	-3.8	-5.0	-4.1
Others	Revenue	1.0	1.0	1.1	0.9	0.8
	Operating profit	0.2	0.4	0.1	2.2	-0.2
Corporate expenses, etc.	Operating profit	-8.7	-12.2	-10.5	-10.6	-9.6
	Broken out: Expense related to investment in growth	-4.9	-5.0	-5.1	-5.4	-4.1
	Broken out: Expense for administration department	-3.7	-8.3	-6.0	-5.5	-4.0
	Broken out: Elimination of intersegment transactions	-0.0	1.0	0.7	0.2	-1.4
Consolidated	Revenue	163.8	168.9	179.9	202.6	158.1
	Operating profit	2.9	2.9	2.3	-5.7	-1.1


1st Quarter of the Year Ending March 31, 2026 : Financial Position



Note: Equity ratio is the ratio of equity attributable to owners of parent to total assets.
Cash and cash equivalents excludes time deposits with maturities of three months or more.


Capital Expenditures, Depreciation & Amortization, and Inventories

CAPITAL EXPENDITURES, DEPRECIATION & AMORTIZATION





■ Capital expenditures ■ Depreciation & amortization

BREAKDOWN OF INVENTORIES





Note: Capital expenditures include right-of-use assets.
Depreciation & amortization includes right-of-use assets, depreciation of property, plant and equipment and amortization of intangible assets obtained by business combination.

1st Quarter of the Year Ending March 31, 2026 : Revenue Breakdown




Note: The outside and inside circles show the breakdown of FY2026/3 revenue of ¥158.1B and FY2025/3 revenue of ¥163.8B, respectively.

Forecast for the Year Ending March 31, 2026 : R&D Expenditures



Note: R&D expenditures includes capitalization of some development expenditures.


Cash Flow History



Note: FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = net increase (decrease) in cash and cash equivalents


Imaging Products Business: Sales Units

SALES IN UNITS BY PRODUCT CATEGORY




Forecast for the Year Ending March 31, 2026: Precision Equipment Business Sales Units

FPD LITHOGRAPHY SYSTEMS SALES
BY GENERATION




SEMICONDUCTOR LITHOGRAPHY
SYSTEMS SALES BY TECHNOLOGY
(INCL. REFURBISHED)



Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of the "Mini Step & Repeat Exposure System."
 The unit sales of new semiconductor lithography systems are 17 units in FY2022/3, 27 units in FY2023/3, 31 units in FY2024/3, 18 units in FY2025/3, and 27 units (forecast) in FY2026/3.


Precision Equipment Business: Sales Units

FPD LITHOGRAPHY SYSTEMS SALES IN UNITS
BY GENERATION



Precision Equipment Business: Sales Units

**SEMICONDUCTOR LITHOGRAPHY SYSTEMS SALES
IN UNITS BY TECHNOLOGY (INCL. REFURBISHED)**



Note: "i-line, etc." part in numbers of semiconductor lithography systems sales include sales numbers of the "Mini Step & Repeat Exposure System."

Forecast for the Year Ending March 31, 2026: Foreign Exchange Impact

	Exchange Rate	Financial Impact from Fluctuation by 1 yen	
	FY2026/3 Forecast for Q2~Q4	Revenue Q2~Q4	Operating Profit Q2~Q4
US \$	¥145	Approx. ¥1.8B	Approx. ¥0.4B
EURO	¥155	Approx. ¥0.6B	Approx. ¥0.2B

Note: The foreign exchange impact above is made on the assumption that emerging-market currencies move according to the influence of US\$ and EURO.

Disclaimer Regarding Forecast and Projections

Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.

